Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
41 hedge funds and large institutions have $573M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 36 closing their positions.
600% more funds holding in top 10
Funds holding in top 10: 1 → 7 (+6)
227% more capital invested
Capital invested by funds: $175M → $573M (+$397M)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
33% less funds holding
Funds holding: 61 → 41 (-20)
53% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$102M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$28.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$9.98M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$9.95M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.43M |
| 4 |
SRCM
Sage Rock Capital Management
New York
|
-$6.62M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.4M |
PRDS Hedge Fund Activity: Q4 2021 in Review
41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q4 2021, worth a combined $573M — up 227% from $175M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of PRDS and 17 opened new positions — a net loss of 19 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Foresite Capital Management V, adding an estimated $102M. The largest seller was Arena Capital Advisors, cutting an estimated $9.98M.
- 41 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q4 2021, down from 61 in Q3 2021.
- Funds reported $573M of Pardes Biosciences, Inc. Common Stock stock for Q4 2021, up 227% quarter-over-quarter.
- 17 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q4 2021 and 36 closed out, a net change of -19 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q4 2021 was Foresite Capital Management V, an estimated $102M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q4 2021 was Arena Capital Advisors, an estimated $9.98M sold.
Based on aggregated 13F filings for Q4 2021.